yed / Incidence not known
agranulocytosis / Delayed / Incidence not known
Moderate
eosinophilia / Delayed / 1.0-7.0
vaginitis / Delayed / 0-5.4
elevated hepatic enzymes / Delayed / 0-4.0
phlebitis / Rapid / 1.7-1.7
leukopenia / Delayed / 0-1.0
thrombocytopenia / Delayed / 0-1.0
hypoprothrombinemia / Delayed / 0-1.0
neutropenia / Delayed / 0-1.0
candidiasis / Delayed / 0-1.0
pseudomembranous colitis / Delayed / 0-1.0
oral ulceration / Delayed / 0-1.0
dysuria / Early / 0-1.0
jaundice / Delayed / 0-1.0
hepatitis / Delayed / 0-1.0
cholestasis / Delayed / 0-1.0
erythema / Early / 0-1.0
chest pain (unspecified) / Early / 0-1.0
dyspnea / Early / 0-1.0
sinus tachycardia / Rapid / 0-1.0
hyperbilirubinemia / Delayed / 0.2-0.2
bleeding / Early / Incidence not known
superinfection / Delayed / Incidence not known
colitis / Delayed / Incidence not known
Mild
diarrhea / Early / 0.5-10.6
nausea / Early / 0.2-7.0
vomiting / Early / 3.0-7.0
diaper dermatitis / Delayed / 3.0-3.0
sinusitis / Delayed / 0-1.0
infection / Delayed / 0-1.0
anorexia / Delayed / 0-1.0
abdominal pain / Early / 0-1.0
flatulence / Early / 0-1.0
dyspepsia / Early / 0-1.0
leukorrhea / Delayed / 0-1.0
drowsiness / Early / 0-1.0
restlessness / Early / 0-1.0
headache / Early / 0-1.0
dizziness / Early / 0-1.0
fever / Early / 0-1.0
rash (unspecified) / Early / 0-1.0
pruritus / Rapid / 0-1.0
urticaria / Rapid / 0-1.0
chills / Rapid / 0-1.0
cough / Delayed / 0-1.0
arthralgia / Delayed / 0-1.0
muscle cramps / Delayed / 0-1.0
injection site reaction / Rapid / Incidence not known
DRUG INTERACTIONS
Amikacin: Cefuroxime's product label states that cephalosporins may potentiate the adverse renal effects of nephrotoxic agents, such as aminoglycosides and loop diuretics. Carefully monitor renal function, especially during prolonged therapy or use of high aminoglycoside doses. The majority of reported cases involve the combination of aminoglycosides and cephalothin or cephaloridine, which are associated with dose-related nephrotoxicity as singular agents. Limited but conflicting data with other cephalosporins have been noted.
Aminoglycosides: Cefuroxime's product label states that cephalosporins may potentiate the adverse renal effects of nephrotoxic agents, such as aminoglycosides and loop diuretics. Carefully monitor renal function, especially during prolonged therapy or use of high aminoglycoside doses. The majority of reported cases involve the combination of aminoglycosides and cephalothin or cephaloridine, which are associated with dose-related nephrotoxicity as singular agents. Limited but conflicting data with other cephalosporins have been noted.
Amoxicillin; Clarithromycin; Lansoprazole: Avoid the concomitant use of proton pump inhibitors (PPIs) and cefuroxime. Drugs that reduce gastric acidity, such as PPIs, can interfere with the oral absorption of cefuroxime axetil and may result in reduced antibiotic efficacy.
Amoxicillin; Clarithromycin; Omeprazole: Avoid the concomitant use of proton pump inhibitors (PPIs) and cefuroxime. Drugs that reduce gastric acidity, such as PPIs, can interfere with the oral absorption of cefuroxime axetil and may result in reduced antibiotic efficacy.
Antacids: Antacids can interfere with the oral absorption of cefuroxime axetil and may result in reduced antibiotic efficacy. If an antacid must be used while a patient is taking cefuroxime, administer the oral dos |
